Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Pathology, Kameda Medical Center, Kamogawa, Japan.
Histopathology. 2022 Dec;81(6):758-769. doi: 10.1111/his.14779. Epub 2022 Sep 12.
The reporting of tumour cellularity in cancer samples has become a mandatory task for pathologists. However, the estimation of tumour cellularity is often inaccurate. Therefore, we propose a collaborative workflow between pathologists and artificial intelligence (AI) models to evaluate tumour cellularity in lung cancer samples and propose a protocol to apply it to routine practice.
We developed a quantitative model of lung adenocarcinoma that was validated and tested on 50 cases, and a collaborative workflow where pathologists could access the AI results and adjust their original tumour cellularity scores (adjusted-score) that we tested on 151 cases. The adjusted-score was validated by comparing them with a ground truth established by manual annotation of haematoxylin and eosin slides with reference to immunostains with thyroid transcription factor-1 and napsin A. For training, validation, testing the AI and testing the collaborative workflow, we used 40, 10, 50 and 151 whole slide images of lung adenocarcinoma, respectively. The sensitivity and specificity of tumour segmentation were 97 and 87%, respectively, and the accuracy of nuclei recognition was 99%. One pathologist's visually estimated scores were compared to the adjusted-score, and the pathologist's scores were altered in 87% of cases. Comparison with the ground truth revealed that the adjusted-score was more precise than the pathologists' scores (P < 0.05).
We proposed a collaborative workflow between AI and pathologists as a model to improve daily practice and enhance the prediction of tumour cellularity for genetic tests.
在癌症样本中报告肿瘤细胞密度已成为病理学家的一项强制性任务。然而,肿瘤细胞密度的评估往往不够准确。因此,我们提出了一种病理学家与人工智能(AI)模型之间的协作工作流程,以评估肺癌样本中的肿瘤细胞密度,并提出了将其应用于常规实践的方案。
我们开发了一种肺腺癌的定量模型,在 50 例病例中进行了验证和测试,并提出了一种协作工作流程,病理学家可以访问 AI 结果,并调整他们最初的肿瘤细胞密度评分(调整评分),我们在 151 例病例中进行了测试。通过与手动注释苏木精和伊红切片并参考免疫组化甲状腺转录因子-1 和 napsin A 进行比较,我们验证了调整评分的准确性。用于训练、验证、测试 AI 和测试协作工作流程的全幻灯片图像分别为 40、10、50 和 151 张肺腺癌全幻灯片图像。肿瘤分割的灵敏度和特异性分别为 97%和 87%,核识别的准确性为 99%。一位病理学家的目测评分与调整评分进行了比较,在 87%的病例中,病理学家的评分发生了改变。与真实情况的比较表明,调整评分比病理学家的评分更准确(P<0.05)。
我们提出了一种 AI 和病理学家之间的协作工作流程,作为一种模型,可以改进日常实践,并提高遗传测试中肿瘤细胞密度的预测。